- Updated Phase II interim results with IPH 1101 in non-Hodgkin’s lymphoma on a larger cohort confirming encouraging trend in complete response rate
- Update on IPH 2101 Phase I trials and new set of pre-clinical data
- Innate Pharma’s lead drug-candidates presented during two oral and five posters sessions, reinforcing the Company’s presence in the hemato-oncology scientific and medical communities
| PR in english | 64.47 KB |
| CP en français | 66.56 KB |